# US 2024/0156906 A1 · Anticoagulant proteins and their use for treating diseases associated with the activation of neutrophils

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0156906 A1
- Document ID: US20240156906A1
- Status: Published application
- Kind: A1
- Application number: 18/394,080
- Filed: 2023-12-22
- Published: 2024-05-16
- Earliest claimed: 2018-02-01
- Assignees: Bioxodes
- Applicants: Bioxodes
- Inventors: Valérie PIREAUX; Stéphanie DEMOULIN; Edmond GODFROID; Joël TASSIGNON; Sandrine DEROCHETTE; Michel GUYAUX
- Web page: https://patentgrep.com/patent/US20240156906A1

## CPC

- A61K 38/1767: {from invertebrates}
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is an Ixodes ricinus salivary gland polypeptide and its use for inhibiting the extrinsic coagulation pathway and for treating and/or preventing diseases and conditions, such as thrombotic events, associated with the recruitment and activation of neutrophils following activation of the extrinsic coagulation pathway.

## Claims

### Claim 1

A method of treating and/or preventing thromboinflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a protein or polypeptide comprising a polypeptide that has at least 85% sequence identity with the amino acid sequence SEQ ID NO: 2.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 2.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said protein or polypeptide binds to activated coagulation factors comprising FXIIa, FXIa, and kallikrein.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said thromboinflammation is selected from the group comprising atherosclerosis, plaque rupture, devices-induced thromboinflammation, thrombosis induced by catheterism and/or stent positioning procedures, thrombosis induced by extracorporeal circulation, thrombus formation following cerebral injuries, coronary artery disease, acute myocardial infraction, cancer-associated thrombosis, metastasis-associated thrombosis, stroke-associated thrombosis, Behcet's disease (BD), antineutrophil cytoplasmic antibody-associated (ANCA) vasculitides, Takayasu arteritis, rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, familial Mediterranean fever, thromboangiitis obliterans (TAO), sepsis, inflammatory bowel diseases, heparin-induced thrombocytopenia, immunothrombosis, thrombosis associated with preeclampsia, thrombotic complication in cell and cell cluster transplantation and in whole organ transplantation or grafts, venous thromboembolism, aneurysms, and skeletal muscle ischemia-reperfusion syndrome.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said thromboinflammation is thrombus formation following cerebral injuries.

### Claim 7 (depends on 5)

The method according to claim 5, wherein said thromboinflammation is stroke-associated thrombosis.

### Claim 8

A method of treating and/or preventing thromboinflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a medicament comprising a protein or polypeptide comprising:
a polypeptide that has at least 85% sequence identity with the amino acid sequence SEQ ID NO: 2, and
at least one pharmaceutically acceptable excipient.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 2.

### Claim 10 (depends on 8)

The method according to claim 8, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 1.

### Claim 11 (depends on 8)

The method according to claim 8, wherein said protein or polypeptide binds to activated factors comprising FXIIa, FXIa, and kallikrein.

### Claim 12 (depends on 8)

The method according to claim 8, wherein said thromboinflammation is selected from the group comprising atherosclerosis, plaque rupture, devices-induced thromboinflammation, thrombosis induced by catheterism and/or stent positioning procedures, thrombosis induced by extracorporeal circulation, thrombus formation following cerebral injuries, coronary artery disease, acute myocardial infraction, cancer-associated thrombosis, metastasis-associated thrombosis, stroke-associated thrombosis, Behcet's disease (BD), antineutrophil cytoplasmic antibody-associated (ANCA) vasculitides, Takayasu arteritis, rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, familial Mediterranean fever, thromboangiitis obliterans (TAO), sepsis, inflammatory bowel diseases, heparin-induced thrombocytopenia, immunothrombosis, thrombosis associated with preeclampsia, thrombotic complication in cell and cell cluster transplantation and in whole organ transplantation or grafts, venous thromboembolism, aneurysms, and skeletal muscle ischemia-reperfusion syndrome.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said thromboinflammation is thrombus formation following cerebral injuries.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said thromboinflammation is stroke-associated thrombosis.
